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ABSTRACT
Objective: For patients with advanced cancer, several
randomised controlled trials have shown that access to
palliative care at least 6 months before death can
improve symptoms, reduce unplanned hospital
admissions, minimise aggressive cancer treatments
and enable patients to make choices about their end-
of-life care, including exercising the choice to die at
home. This study determines in a UK population the
duration of palliative care before death and explores
influencing factors.
Design: This retrospective cohort study analysed
referrals to three specialist palliative care services; a
hospital-based inpatient palliative care team, and two
community-based services (hospices). For each patient
referred to any of the above services we identified the
date of first referral to that team and calculated the
median interval between first referral and death. We
also calculated how referral time varied by age, sex,
diagnosis and type of palliative care service.
Participants: 4650 patients referred to specialist
palliative care services in Leeds UK between April 2012
and March 2014.
Results: Median age of the sample was 75 years.
3903 (84.0%) patients had a diagnosis of cancer. Age,
diagnosis and place of referral were significant
predictors of duration of palliative care before death.
Age was independently associated ( J=2 672 078, z=
−392046.14, r=0.01) with duration of palliative care
regardless of diagnosis. Patients over 75 years have 29
fewer days of palliative care than patients under 50.
Patients with non-cancer diagnoses have 13 fewer days
of palliative care than patients with cancer. Additionally,
patients referred to hospital palliative care receive 24.5
fewer days palliative care than those referred to
community palliative care services.
Conclusions: The current timing of referral to
palliative care may limit the benefits to patients in
terms of improvements in end-of-life care, particularly
for older patients and patients with conditions other
than cancer.
INTRODUCTION
Specialist palliative care services aim to
relieve suffering and improve quality of life
for people with advanced diseases. For
patients with advanced cancer, several rando-
mised controlled trials1–5 have shown that
early access to palliative care can improve
symptoms, reduce unplanned hospital admis-
sions, minimise aggressive cancer treatments
and enable patients to make choices about
their end-of-life care, including exercising
the choice to die at home, which for more
than half of patients with cancer is their
expressed preference.5 The trials from which
this evidence is derived were conducted in
North America and the studies vary widely in
their deﬁnition of what constitutes palliative
care services and who provides them.
Common components were an assessment
and several follow-up consultations by special-
ist palliative care teams over a period of 2–
3 months. Where reported, patients were
Strengths and limitations of this study
▪ To the best of our knowledge, this is the largest
UK cohort study undertaken to explore duration
of palliative care in patients with cancer and non-
cancer diagnoses.
▪ The data used in this study are derived from a
live clinical system and as such are likely to rep-
resent errors or omissions inherent within that
system.
▪ As the data were anonymised, we were unable to
identify which patients were referred to commu-
nity and hospital palliative care. This may mean
that for some patients their first contact with pal-
liative care services could have occurred earlier
than reported here.
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recruited and received these interventions about 6–
14 months before their death.1–5 Collectively, these data
suggest that a dose of three to four palliative care con-
tacts applied about 6 months before death is associated
with better end-of-life care.
The accumulating evidence to support early referral1–10
is beginning to inﬂuence policy within the USA. Following
a randomised phase III trial in patients with small cell lung
cancer, which demonstrated the beneﬁt of early palliative
care involvement in terms of quality of life and survival in
2010,1 the American Society of Clinical Oncology issued
guidance recommending that palliative care should be
considered early in the course of illness for any patient
with metastatic cancer or high symptom burden.7 Despite
this growing evidence base, within routine clinical practice
in the UK palliative care clinicians report that many refer-
rals are made in the last weeks or days of life. This study
determines in a UK population the duration of palliative
care before death and explores inﬂuencing factors.
METHODS
Data and patients
We analysed referrals to three specialist palliative care ser-
vices in Leeds, UK over a 2-year period (April 2012 to
March 2014) relating to 4650 deceased patients. One
service was a hospital-based inpatient palliative care team
serving an acute hospital and tertiary cancer centre, and
two were community-based services (hospices) compris-
ing 18 and 32 inpatient beds, each with its own commu-
nity home care team. For each palliative care service a
data manager employed within each organisation pro-
vided anonymised data from their electronic medical
record system. For each patient referred to any of the
above services, we identiﬁed the date of ﬁrst referral to
that team (referrals to community (hospice) palliative
care (CPC) can be made by any health professional or
the patient; referral to hospital palliative care (HPC) is
typically by a health professional within the acute hospital
in which the HPC team is based). We calculated the
median interval between ﬁrst referral and death. We also
calculated how referral time varied by age, sex, diagnosis
and type of palliative care service. The data were systemat-
ically checked for outliers, inconsistencies, ambiguous
diagnoses and missing data (eg, no date of death). The
main variables of interest were age at referral (in years),
median time from referral to death (in days), referral
location (acute hospital or community hospice), diagnos-
tic grouping (cancer, non-cancer) and subcategories of
diagnosis for cancer and non-cancer conditions, as out-
lined in table 1.
Statistical analysis
All referred adults (n=4650) were included in the
descriptive analysis. Median times to death were calcu-
lated and the variability was summarised using median
absolute deviation (MAD). The median deviation is a
measure of scale based on the median of the absolute
deviations from the median of the distribution.11 MAD
was used as it is a measure of statistical dispersion that is
resistant to outliers. Comparisons between median days
from date of referral to death were performed using
Mann-Whitney U for cancer versus non-cancer and hos-
pital versus hospice referral. Comparisons for age (<50,
50–74 and 75+ years) were performed using the
Kruskal-Wallis test, followed by the Jonckheere-Terpstra
test.12 These analyses were performed using SPSS V.22.0.
We used median quantile regression to investigate the
association between age and sex-standardised median
days to death for diagnosis (cancer vs non-cancer) and
place of referral (hospital vs hospice). Diagnosis and
place of referral were modelled using multivariable quan-
tile regression analyses. This model permits estimation of
how the conditional median, or other quantiles (eg, 10th
and 90th centile), of a dependent variable y changes with
an independent variable x. Diagnosis and place of refer-
ral were then included into this model. The model was
generated using the qreg command in STATA. Two-tailed
p values <0.01 were considered signiﬁcant.
Patient involvement
Two patients with cancer are co-investigators on the
research programme of which the study is part and have
informed its design and conduct. They are supporting
the active dissemination of the study ﬁndings to patients
and carers through patient and public involvement net-
works in a format that can be readily understood by
patients, carers and health service commissioners.
RESULTS
Sample characteristics
4650 patients were included in the analysis. 2272 women
and 2378 men. The median age of the sample was
75 years; 272 patients were under 50 years, 2014 were
50–74 years of age and 2354 were 75 years or over. In
total, 3903 patients had a diagnosis of cancer, 747 had
conditions other than cancer. The median duration of
palliative care for the whole study population was
34 days (MAD=29 days, indicating that half of the study
population had a duration of palliative care that
deviated from the median by up to 29 days).
Type of palliative care service
In total, 2746 patients were referred to CPC teams and
1904 to a HPC team. When the services were considered
separately (community and hospital), we found the length
of palliative care was longer for patients referred to CPC;
median 46 days (MAD=38 days) compared with 20 days
(MAD=17 days) for referrals to HPC (U=1925555.5,
p<0.01, r=−0.22).
Diagnosis and duration of palliative care
The duration of palliative care varied depending on
diagnosis. The median duration of palliative care for
patients with cancer was 37 days (MAD=31 days).
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Patients with conditions other than cancer had signiﬁ-
cantly shorter duration of palliative care than patients
with cancer, overall median 16 days (MAD=14 days)
(U=1 110 511, p<0.01, r=−0.15); longer for CPC (22 days
CPC, MAD 19 days) and shorter for HPC (13 days HPC,
MAD 11 days).
Within the patient with cancer population, there was
variation in duration of palliative care across the differ-
ent cancer types; patients with breast or prostate cancer
had the longest time between referral and death
(median days of 43.5 and 48 days, respectively) and
patients with haematological or head and neck cancers
the shortest (both with a median of 26 days). A
Kruskal-Wallis H test showed that there was a statistically
signiﬁcant difference in number of days from referral to
death between cancer diagnoses, χ2(14)=58.337,
p=<0.001 (ﬁgure 1). A breakdown of diagnosis categor-
ies for the non-cancer population was only available for
the referrals to CPC. These are shown in ﬁgure 2.
Patients with dementia or patients who had a stroke had
the shortest duration of palliative care before death
(median 9 and 5 days, respectively), and patients with
motor neuron disease had longest (median 83 days).
Age and duration of palliative care
We found a linear relationship between age and dur-
ation of palliative care. Patients over 75 years had a
median of 29 days (MAD=25 days) palliative care before
death, patients between 50 and 74 years, 38 days
(MAD=31 days) and those under 50 years had most,
54.5 days (MAD=47 days), ( J=2 672 078, z=−392046.14,
r=0.01).
Multivariable quantile regression
Univariate analysis showed age, diagnosis and place of
referral as signiﬁcant predictors of duration of palliative
care before death. The multivariable analysis showed
that age is independently associated with duration of
Table 1 Patient characteristics in relation to referral to community and hospital palliative care
Community PC n (%) Hospital PC n (%) Total n (%)
Total 2746 (59.1) 1904 (40.9) 4650
Sex
Men 1420 (51.7) 958 (50.3) 2378 (51.1)
Women 1326 (48.3) 946 (49.7) 2272 (48.9)
Diagnosis
Cancer 2346 (85.5) 1557 (81.8) 3903 (83.9)
Gynaecological 120 (5.1) 145 (9.3) 265 (6.8)
Haematological 105 (4.5) 26 (1.7) 131 (3.4)
Kidney 66 (2.8) 46 (3.0) 112 (2.9)
Colorectal 253 (10.8) 153 (9.8) 406 (10.4)
Upper GI 394 (16.8) 221 (14.2) 615 (15.8)
Lung 659 (28.1) 232 (14.9) 891 (22.8)
Brain 79 (3.4) 34 (2.2) 113 (2.9)
Head and neck 58 (2.5) 65 (4.2) 123 (3.2)
Breast 132 (5.6) 172 (11.0) 304 (7.8)
Bladder 76 (3.2) 54 (3.5) 130 (3.3)
Liver 45 (1.9) 32 (2.1) 77 (2.0)
Prostate 146 (6.2) 106 (6.8) 252 (6.5)
Skin 44 (1.9) 85 (5.5) 129 (3.3)
Unknown origin 130 (5.5) 51 (3.3) 181 (4.6)
Other cancer 39 (1.7) 135 (8.7) 174 (4.5)
Non-cancer 400 (14.6) 347 (18.2) 747 (16.1)
Dementia 52 (13.0) − 52 (13.0)
Stroke 19 (4.8) − 19 (4.8)
Degenerative disease 8 (2.0) − 8 (2.0)
Other neurological 27 (6.8) − 27 (6.8)
Heart failure 110 (27.5) − 110 (27.5)
Other lung 96 (24.0) − 96 (24.0)
Liver failure 16 (4.0) − 16 (4.0)
Kidney failure 36 (9.0) − 36 (9.0)
Other non-cancer 36 (9.0) − 36 (9.0)
Non-classified diagnosis − 347 (46.5) 347 (46.5)
Age, years
<50 years 110 (4) 172 (9) 282 (6)
50–74 years 1082 (39.4) 932 (48.9) 2014 (43.3)
75+ years 1554 (56.6) 800 (42) 2354 (50.6)
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palliative care regardless of diagnosis, table 2. Patients
over 75 years have 29 fewer days of palliative care than
patients under 50. Even when controlling for age and
sex, patients with non-cancer diagnoses have 13 fewer
days of palliative care than patients with cancer.
Additionally, patients referred in hospital receive 24.5
fewer days of palliative care than those referred in the
community.
DISCUSSION
This is the ﬁrst population-level study that quantiﬁes dur-
ation of palliative care before death, and identiﬁes sig-
niﬁcantly different durations of palliative care for older
patients and those with non-cancer diagnoses.
Comparison with other studies
In terms of studies exploring duration of palliative care
globally, our cohort is second only in terms of popula-
tion size to a US study exploring duration of palliative
care in patients with heart failure.13 We found the
median duration of palliative care in our cohort to be
34 days, signiﬁcantly shorter than the 6 months the
research evidence suggests is optimal.1–5 While the dur-
ation of palliative care in our cohort appears to be
similar to that observed in studies in the USA2 and
Italy,14 15 direct comparison is challenging due to the
differing characteristics of the palliative services and the
components of care they provide. It is however possible
to broadly categorise the literature into those studies
reporting exposure to hospital-based palliative care ser-
vices and those reporting community or hospice-based
services. Studies from the UK,16 17 the USA,18 19 Korea20
and Singapore21 report the median duration of HPC to
range from 14.4 to 57 days and studies reporting CPC
from Canada,22 Italy15 and Ireland7 report duration to
range from 40 to 70 days. These studies provide useful
context to the data reported here (20 days to HPC;
46 days CPC) and show the timing of referral to be con-
sistent with that reported in the international literature.
Having a cancer diagnosis is the primary determinant
of access to specialist palliative care. During 2012 to
2013, 88% of palliative care inpatients and 75% of new
referrals to hospital support and outpatient services in
the UK were for people with a cancer diagnosis, even
though cancer accounts for only around 29% of
deaths.23 24 In our study population, 81% had a diagno-
sis of cancer which is consistent with the existing evi-
dence that patients with cancer are more likely to access
palliative care. Extending palliative care to people with
non-cancer diagnoses is a key objective of end-of-life
care strategies across the UK; however, access to palliative
care for patients with non-cancer is hindered by less pre-
dictable disease trajectories and greater difﬁculty in
Figure 1 Duration of palliative care in relation to cancer diagnosis.
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identifying a terminal stage. Consistent with this, we
found that patients with cancer had ∼13 days more pal-
liative care than patients with non-cancer. It is already
well evidenced10 11 that patients with non-cancer are dis-
advantaged in terms of access to palliative care but it has
not been reported previously that the inequity extends
to the duration of care.
We found that increasing age is associated with shorter
duration of palliative care. The most recent minimum
data set on palliative care activity shows older people are
disadvantaged in terms of access; 29% of people acces-
sing specialist palliative care are in the 25–64 age group
despite this age group only accounting for 13% of
deaths. Whereas people aged 85 or over account for
39% of deaths but represent only 16.4% of referrals to
palliative care services.25 Our study is the ﬁrst to identify
and quantify the shorter duration of palliative care in
relation to age and so adds to this evidence base. Older
Figure 2 Duration of palliative care in relation to non-cancer diagnosis.
Table 2 Univariable and multivariable model for duration of palliative care
Variable Univariable model Multivariable model
Age
<50 years − −
50–74 years −17 (−27.06, −10.94)+ −20.5 (−29.53, −11.47)+
75 years and older −26 (−35.13, −16.87)+ −29 (−38.04, −19.96)+
Sex
Women − −
Men −5 (−8.95, −1.05) −2.5 (−6.66, 1.66)
Diagnosis
Cancer − −
Non-cancer −21 (−26.12, −15.88)+ −13.5 (−19.24, −7.76)+
Place of referral
Hospice − −
Hospital −28 (−32.25, −23.75)+ −24.5 (−28.79, −20.21)+
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people are therefore disadvantaged in access to, and
duration of, palliative care before death.
Limitations
This study has limitations. First, it is based in a single UK
city and although our ﬁndings are consistent with those
reported elsewhere, Leeds is particularly well provi-
sioned in terms of palliative care services and our ﬁnd-
ings may not therefore be representative of practice in
other settings with less robust provision. Second, as
de-identiﬁed data were used, we were unable to identify
situations where a referral to HPC and CPC services had
occurred. In Leeds, 17% of patients referred to HPC ser-
vices receive a subsequent CPC referral; therefore, we
expect this extent of overlap to be evident in the data
reported here.
Third, as retrospective routinely collected clinical data
were used, we do not have data on date of diagnosis,
which prevents us from relating the duration of palliative
care services to the duration of clinical awareness of
disease. Late diagnosis may be a key factor in late refer-
ral, though the almost universally short duration of pal-
liative care in our cohort suggests that this factor is
unlikely to account for the observed referral pattern.
CONCLUSIONS
This study shows that the current timing of referral to
palliative care may limit the beneﬁts to patients in terms
of improvements in end-of-life care, particularly for
older patients and patients with conditions other than
cancer. Research is now urgently needed to better
understand how the duration of palliative care reported
here impacts on the quality of end-of-life care in order
to develop and evaluate service-level interventions.
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